Skip to content

Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery

Treatment of Depression Following Bypass Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00091962
Enrollment
453
Registered
2004-09-23
Start date
2003-08-31
Completion date
2009-12-31
Last updated
2016-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Coronary Disease, Heart Diseases, Depression

Brief summary

The purpose of this study is to treat depression in patients who have undergone coronary artery bypass graft (CABG).

Detailed description

BACKGROUND: Cardiovascular disease morbidity and mortality is an important health issue. Depression has emerged as a risk factor for increased morbidity and mortality in patients with coronary heart disease. CABG is a surgical procedure that is specifically directed to improvement in quality of life for patients with severe coronary artery disease, though its impact on mortality is questionable. Patients with depression after CABG are found to not demonstrate sufficient improvement in quality of life, resulting in a significantly higher level of healthcare costs. DESIGN NARRATIVE: In this randomized study, 300 patients who show elevated levels of depressive symptoms at 3 to 5 days following CABG and at 2 weeks after hospital discharge will be recruited. They will be randomized to receive either 1) their physician's usual care for depression, or 2) a stepped collaborative care program involving a telephone-based nurse care manager. The nurse care manager will contact patients at regular intervals to assess treatment preferences for depression (e.g., counseling, self-management workbook, pharmacotherapy, or specialty referral), promote adherence with care, and monitor the therapeutic response in concert with patient's primary care physicians and under the supervision of a study clinician. One hundred and fifty nondepressed post-CABG patients will be randomly selected to serve as a control cohort to facilitate comparisons with the depressed patients on various baseline and follow-up measures, and to better understand the benefits derived from depression treatment (total N=450). Blinded telephone assessments will be conducted at 2, 4, 8, and 12 months post CABG and then every 6 months until the last patient completes his/her 8-month assessment (range: 8-44 months follow-up). Intent-to-treat analyses will be used to test the primary hypothesis that the intervention will produce at least a clinically meaningful 0.5 effect size improvement in health related quality of life (HRQoL) at 8 months post CABG, as measured by the SF-36 Mental Component Summary score, compared to patients who receive their primary care physician's usual care for depression. The secondary hypotheses are that compared to usual care patients, intervention patients will 1) experience higher levels of functional status, and lower levels of depressive symptoms, risk for future cardiovascular events, and health services costs, and 2) report similar levels of HRQoL as nondepressed post-CABG patients. Providing evidence-based, stepped, collaborative care treatment for post-CABG depression may be an ideal method for organized health care delivery systems to improve outcomes. The focus on HRQoL and health services costs will facilitate comparisons of the benefits derived from the intervention to that of other established treatments of cardiovascular risk factors and care for other chronic conditions.

Interventions

BEHAVIORALPsychoeducation; Treatment recommendations

Counseling program

Recommendations to patients' PCP for medication to treat depression

OTHERUsual Care

Physicians' Usual care

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Recently underwent CABG (combined or redo procedure) at one of 8 Pittsburgh area study hospitals * A PHQ score greater than 10 OR if nondepressed control, a PHQ score less than 5 at both 2 days post CABG to the date of discharge following CABG and when reassessed 2 weeks after hospital discharge * Folstein Mini-Mental State Examination (MMSE) score greater than or equal to 24 * Able to be evaluated and treated for depression as an outpatient post CABG * Has a household telephone

Exclusion criteria

* Presently in treatment with a mental health specialist * Actively suicidal * History of psychotic illness * History of bipolar illness according to subject self-report and past medical history * Current alcohol dependence or other substance abuse as evidenced by chart review and the CAGE questionnaire * Organic mood syndromes, including those secondary to medical illness or drugs * Presence of non-cardiovascular conditions that are likely to be fatal within 1 year * Unstable medical condition as indicated by history, physical, and/or laboratory findings * Previous enrollment in the study cohort * Non-English speaking, illiterate, or possessing any other communication barrier * If nondepressed control, current or previous diagnosis or treatment of depression

Design outcomes

Primary

MeasureTime frameDescription
Generic Mental Health-Related Quality of LifeMeasured 8 months post-CABGThe 36-item Medical Outcomes Study Form (v.2) Mental Component Scale (SF-36 MCS). Range 0-100; Population norm is 50 with standard deviation of 10. Higher scores are better. Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. 2nd ed. Boston, MA: New England Medical Center; 1994.

Secondary

MeasureTime frameDescription
Hamilton Rating Scale for Depression8 months post CABGThe 17-item Depression Interview and Structured Hamilton (DISH) version of the Hamilton Rating Scale for Depression Standard provides an accurate DSM-IV diagnosis of a cardiac patient's mood disorder and a reliable HRS-D score. Range 0-52. Higher scores are worse. Psychosom Med. 2002;64(6):897-905
Generic Physical Health-Related Quality of Life8 months post CABGThe 36-item Medical Outcomes Study Form (v.2) Physical Component Scale (SF-36 PCS). Range 0-100; Population norm is 50 with standard deviation of 10. Higher scores are better. Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. 2nd ed. Boston, MA: New England Medical Center; 1994.
Disease-Specific Health-Related Quality of Life8 months post CABGThe 12-item Duke Activity Status Index (DASI). Scores range from 0-58.2, and higher scores the better the functional capacity (Am J Cardiol. 1989;64(10):651-654).

Countries

United States

Participant flow

Participants by arm

ArmCount
Depressed Intervention
Collaborative care program for depression involving a telephone-based nurse care manager Counseling: Counseling program Pharmacotherapy: Medication to treat depression
150
Depressed Usual Care
Control group will receive usual care for depression Usual Care: Usual care for depression
152
Non-Depressed Control
Observational only
151
Total453

Baseline characteristics

CharacteristicDepressed InterventionDepressed Usual CareNon-Depressed ControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
65 Participants68 Participants91 Participants224 Participants
Age, Categorical
Between 18 and 65 years
85 Participants84 Participants60 Participants229 Participants
Age, Continuous64 years
STANDARD_DEVIATION 10.8
64 years
STANDARD_DEVIATION 11.2
66 years
STANDARD_DEVIATION 9.6
65 years
STANDARD_DEVIATION 10
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants0 Participants2 Participants5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
147 Participants152 Participants149 Participants448 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants0 Participants1 Participants2 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants2 Participants2 Participants
Race (NIH/OMB)
Black or African American
17 Participants10 Participants25 Participants52 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
132 Participants142 Participants122 Participants396 Participants
Region of Enrollment
United States
150 participants152 participants151 participants453 participants
Sex: Female, Male
Female
69 Participants56 Participants56 Participants181 Participants
Sex: Female, Male
Male
81 Participants96 Participants95 Participants272 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 1500 / 1520 / 151
serious
Total, serious adverse events
0 / 1500 / 1520 / 151

Outcome results

Primary

Generic Mental Health-Related Quality of Life

The 36-item Medical Outcomes Study Form (v.2) Mental Component Scale (SF-36 MCS). Range 0-100; Population norm is 50 with standard deviation of 10. Higher scores are better. Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. 2nd ed. Boston, MA: New England Medical Center; 1994.

Time frame: Measured 8 months post-CABG

ArmMeasureValue (MEAN)Dispersion
Depressed InterventionGeneric Mental Health-Related Quality of Life50.0 units on a scaleStandard Error 1
Depressed Usual CareGeneric Mental Health-Related Quality of Life46.2 units on a scaleStandard Error 1.1
Non-Depressed ControlGeneric Mental Health-Related Quality of Life57.2 units on a scaleStandard Error 0.5
Secondary

Disease-Specific Health-Related Quality of Life

The 12-item Duke Activity Status Index (DASI). Scores range from 0-58.2, and higher scores the better the functional capacity (Am J Cardiol. 1989;64(10):651-654).

Time frame: 8 months post CABG

ArmMeasureValue (MEAN)Dispersion
Depressed InterventionDisease-Specific Health-Related Quality of Life25.2 units on a scaleStandard Error 1
Depressed Usual CareDisease-Specific Health-Related Quality of Life21.4 units on a scaleStandard Error 1
Non-Depressed ControlDisease-Specific Health-Related Quality of Life33.2 units on a scaleStandard Error 1.1
Secondary

Generic Physical Health-Related Quality of Life

The 36-item Medical Outcomes Study Form (v.2) Physical Component Scale (SF-36 PCS). Range 0-100; Population norm is 50 with standard deviation of 10. Higher scores are better. Ware J, Kosinski M, Keller S. SF-36 Physical and Mental Health Summary Scales: A User's Manual. 2nd ed. Boston, MA: New England Medical Center; 1994.

Time frame: 8 months post CABG

ArmMeasureValue (MEAN)Dispersion
Depressed InterventionGeneric Physical Health-Related Quality of Life44.0 participantsStandard Error 0.8
Depressed Usual CareGeneric Physical Health-Related Quality of Life41.4 participantsStandard Error 0.8
Non-Depressed ControlGeneric Physical Health-Related Quality of Life48.7 participantsStandard Error 0.7
Secondary

Hamilton Rating Scale for Depression

The 17-item Depression Interview and Structured Hamilton (DISH) version of the Hamilton Rating Scale for Depression Standard provides an accurate DSM-IV diagnosis of a cardiac patient's mood disorder and a reliable HRS-D score. Range 0-52. Higher scores are worse. Psychosom Med. 2002;64(6):897-905

Time frame: 8 months post CABG

ArmMeasureValue (MEAN)Dispersion
Depressed InterventionHamilton Rating Scale for Depression9.0 units on a scaleStandard Error 0.7
Depressed Usual CareHamilton Rating Scale for Depression11.4 units on a scaleStandard Error 0.7
Non-Depressed ControlHamilton Rating Scale for Depression3.8 units on a scaleStandard Error 0.3
p-value: 0.001Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026